Stock listing
NYSE American:RGNT Regentis Biomaterials Ltd. Stock
Home listing (NYSE American) of Regentis Biomaterials Ltd.
Follow Regentis Biomaterials Ltd. into a list and get an email when it puts out news.
Share price · AMEX:RGNT
$0.719 USD -0.121 (-14.4%)
Close on Nov 20, 2026
- Day range
- $0.712 – $0.889 USDNov 20, 2026
- Volume
- 122,345 sharesNov 20, 2026
- Market cap
- $5.05M USDAt the close on Nov 20, 2026 · price × 7.02M shares outstanding
- Traded on an average day
- $79,982 USDMedian day 24,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:RGNT · Home | $0.719 USD | -0.121 (-14.4%) | 122,345 | $0.880 | $0.889 | $0.712 | $0.840 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:RGNT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.719 | -0.121 | -14.4% | $0.880 | $0.889 | $0.712 | 122,345 | |
| $0.840 | -0.300 | -26.3% | $0.840 | $1.080 | $0.811 | 179,762 | |
| $1.140 | -0.080 | -6.6% | $1.215 | $1.215 | $1.140 | 9,157 | |
| $1.220 | +0.030 | +2.5% | $1.230 | $1.230 | $1.140 | 13,014 | |
| $1.190 | -0.040 | -3.3% | $1.310 | $1.310 | $1.190 | 12,579 | |
| $1.230 | -0.020 | -1.6% | $1.240 | $1.290 | $1.220 | 23,600 | |
| $1.250 | -0.020 | -1.6% | $1.270 | $1.270 | $1.180 | 25,100 | |
| $1.270 | -0.060 | -4.5% | $1.340 | $1.340 | $1.225 | 41,300 | |
| $1.330 | +0.060 | +4.7% | $1.315 | $1.340 | $1.190 | 204,800 | |
| $1.270 | +0.080 | +6.7% | $1.180 | $1.690 | $1.180 | 220,300 | |
| $1.190 | +0.020 | +1.7% | $1.172 | $1.220 | $1.160 | 23,400 | |
| $1.170 | -0.150 | -11.4% | $1.300 | $1.355 | $1.170 | 90,300 | |
| $1.320 | -0.050 | -3.6% | $1.370 | $1.410 | $1.264 | 18,300 | |
| $1.370 | 0.000 | 0.0% | $1.360 | $1.430 | $1.340 | 8,600 | |
| $1.370 | 0.000 | 0.0% | $1.360 | $1.440 | $1.360 | 15,300 | |
| $1.370 | +0.010 | +0.7% | $1.420 | $1.420 | $1.310 | 24,900 | |
| $1.360 | +0.130 | +10.6% | $1.280 | $1.470 | $1.265 | 61,800 | |
| $1.230 | -0.060 | -4.7% | $1.260 | $1.300 | $1.230 | 17,600 | |
| $1.290 | +0.030 | +2.4% | $1.270 | $1.415 | $1.250 | 27,000 | |
| $1.260 | -0.020 | -1.6% | $1.300 | $1.320 | $1.260 | 25,200 | |
| $1.280 | -0.120 | -8.6% | $1.420 | $1.420 | $1.280 | 18,400 | |
| $1.400 | -0.090 | -6.0% | $1.480 | $1.480 | $1.400 | 50,700 | |
| $1.490 | +0.020 | +1.4% | $1.510 | $1.559 | $1.484 | 14,200 | |
| $1.470 | -0.010 | -0.7% | $1.530 | $1.540 | $1.470 | 13,800 | |
| $1.480 | -0.010 | -0.7% | $1.440 | $1.600 | $1.440 | 36,100 | |
| $1.490 | -0.060 | -3.9% | $1.600 | $1.600 | $1.460 | 23,500 | |
| $1.550 | +0.040 | +2.6% | $1.550 | $1.560 | $1.500 | 14,300 | |
| $1.510 | -0.115 | -7.1% | $1.650 | $1.650 | $1.450 | 132,600 | |
| $1.625 | -0.005 | -0.3% | $1.630 | $1.670 | $1.590 | 33,400 | |
| $1.630 | +0.030 | +1.9% | $1.620 | $1.645 | $1.600 | 36,100 | |
| $1.600 | -0.100 | -5.9% | $1.670 | $1.740 | $1.600 | 22,200 | |
| $1.700 | +0.070 | +4.3% | $1.690 | $1.730 | $1.650 | 172,800 | |
| $1.630 | -0.020 | -1.2% | $1.640 | $1.690 | $1.630 | 17,000 | |
| $1.650 | -0.020 | -1.2% | $1.670 | $1.740 | $1.650 | 34,000 | |
| $1.670 | -0.180 | -9.7% | $1.830 | $1.860 | $1.660 | 109,500 | |
| $1.850 | +0.020 | +1.1% | $1.850 | $1.874 | $1.780 | 29,000 | |
| $1.830 | +0.020 | +1.1% | $1.860 | $1.880 | $1.800 | 9,000 | |
| $1.810 | -0.040 | -2.2% | $1.870 | $1.980 | $1.810 | 22,200 | |
| $1.850 | -0.040 | -2.1% | $1.920 | $1.920 | $1.800 | 58,600 | |
| $1.890 | -0.090 | -4.5% | $1.950 | $1.970 | $1.855 | 7,600 | |
| $1.980 | -0.060 | -2.9% | $2.060 | $2.080 | $1.900 | 17,200 | |
| $2.040 | -0.060 | -2.9% | $2.080 | $2.080 | $2.000 | 25,000 | |
| $2.100 | +0.010 | +0.5% | $2.135 | $2.150 | $2.050 | 15,100 | |
| $2.090 | -0.140 | -6.3% | $2.170 | $2.170 | $2.090 | 41,200 | |
| $2.230 | +0.420 | +23.2% | $1.850 | $2.480 | $1.850 | 440,400 | |
| $1.810 | +0.060 | +3.4% | $1.800 | $1.890 | $1.730 | 22,800 | |
| $1.750 | -0.050 | -2.8% | $1.820 | $1.870 | $1.750 | 20,607 | |
| $1.800 | -0.010 | -0.6% | $1.810 | $1.850 | $1.740 | 27,400 | |
| $1.810 | -0.070 | -3.7% | $1.890 | $1.890 | $1.750 | 194,400 | |
| $1.880 | -0.010 | -0.5% | $1.900 | $1.960 | $1.875 | 16,600 | |
| $1.890 | -0.070 | -3.6% | $2.020 | $2.020 | $1.890 | 16,542 | |
| $1.960 | -0.050 | -2.5% | $2.010 | $2.010 | $1.915 | 12,800 | |
| $2.010 | -0.030 | -1.5% | $2.060 | $2.070 | $1.980 | 10,500 | |
| $2.040 | +0.070 | +3.6% | $2.000 | $2.040 | $1.920 | 55,800 | |
| $1.970 | 0.000 | 0.0% | $1.940 | $2.000 | $1.940 | 15,900 | |
| $1.970 | -0.050 | -2.5% | $2.060 | $2.060 | $1.940 | 54,300 | |
| $2.020 | -0.040 | -1.9% | $2.050 | $2.090 | $2.020 | 14,500 | |
| $2.060 | +0.020 | +1.0% | $2.040 | $2.110 | $2.005 | 38,500 | |
| $2.040 | +0.040 | +2.0% | $2.000 | $2.140 | $2.000 | 24,400 | |
| $2.000 | -0.060 | -2.9% | $2.100 | $2.100 | $2.000 | 19,636 | |
| $2.060 | -0.010 | -0.5% | $2.120 | $2.120 | $2.060 | 8,200 | |
| $2.070 | -0.020 | -1.0% | $2.080 | $2.155 | $2.040 | 19,100 | |
| $2.090 | -0.070 | -3.2% | $2.100 | $2.140 | $2.000 | 19,800 | |
| $2.160 | +0.060 | +2.9% | $2.150 | $2.180 | $1.960 | 25,600 | |
| $2.100 | +0.040 | +1.9% | $2.050 | $2.170 | $2.050 | 37,200 | |
| $2.060 | -0.170 | -7.6% | $2.140 | $2.220 | $2.060 | 46,000 |
- Ticker
- NYSE American:RGNT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 23 slides
Latest news
Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
Nov 9, 2026
Closed $1.27 (+6.7%) on Nov 9, 2026
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
Oct 12, 2026
Closed $1.63 (+1.9%) on Oct 12, 2026
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Sep 11, 2026
Closed $1.89 (-3.6%) on Sep 11, 2026
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Jul 20, 2026
Closed $2.00 (-16.0%) on Jul 20, 2026
Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
Jul 16, 2026
Closed $2.22 (-8.6%) on Jul 16, 2026
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
Jul 15, 2026
Closed $2.43 (-4.3%) on Jul 15, 2026
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
Jun 17, 2026
Closed $4.29 (-9.7%) on Jun 18, 2026
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
Jun 8, 2026
Closed $1.28 (-3.0%) on Jun 8, 2026
Regentis Biomaterials (RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones
Jun 1, 2026
Closed $1.63 (-11.9%) on Jun 1, 2026
Regentis Biomaterials (RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant
May 29, 2026
Closed $1.85 (-6.6%) on May 29, 2026
Regentis Biomaterials Ltd. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 13 in the last 12 months · 13 in all · newest Nov 9, 2026 · oldest 2025
- Decks
- 4 decks · latest September 2026
Where Regentis Biomaterials Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:RGNT · Home listing · This page | NYSE American | United States | USD |
| BOATS:RGNT | BOATS | United States | USD |
Valuation
Price/book 0.7× against a median of 1.3×: 5th lowest of 11 Medical devices & supplies companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.90M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.00
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Regentis Biomaterials Ltd. · AMEX:RGNT | US$5.05M | −US$3.90M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.00 |
| NeuroOne Medical Technologies Corporation · NASDAQ:NMTC | US$5.94M | US$3.89M | n/a | 0.4× | n/a | 1.6× | −78.6% | 0.0× | 1.07 |
| Neola Medical AB · OMXSTO:NEOLA | US$5.47M | US$5.08M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| ENDRA Life Sciences Inc. · NASDAQ:NDRA | US$5.36M | US$3.85M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.07 |
| MEKICS Co., Ltd. · KRX:058110 | US$5.23M | US$2.04M | 6.6× | 0.2× | 1.3× | 0.2× | 7.7% | 0.1× | n/a |
| PT Hetzer Medical Indonesia Tbk · IDX:MEDS | US$5.16M | US$5.45M | n/a | n/a | n/a | 1.8× | n/a | 0.1× | n/a |
| SeaStar Medical Holding Corporation · NASDAQ:ICU | US$4.97M | US$981,429 | n/a | 0.5× | n/a | 10.6× | −678.2% | 0.0× | 1.44 |
| WORK Medical Technology Group LTD · NASDAQ:WOK | US$4.84M | US$8.21M | n/a | 0.8× | n/a | 0.2× | −10.9% | 0.2× | 2.76 |
| Kelyniam Global, Inc. · OTC:KLYG | US$4.56M | US$4.84M | n/a | 1.4× | 31.9× | 6.6× | −6.0% | 0.6× | 1.15 |
| Meihua International Medical Technologies Co., Ltd. · OTC:MHUAF | US$4.53M | −US$1.63M | 0.7× | −0.0× | −0.2× | 0.0× | 11.0% | 0.1× | 0.62 |
| Aurora Spine Corp. · TSXV:ASG | US$4.36M | US$6.91M | n/a | 0.4× | 45.6× | 1.5× | −7.0% | 1.0× | -0.13 |
| Median of the others | US$5.07M | US$4.37M | 3.7× | 0.4× | 16.6× | 1.3× | −7.0% | 0.1× | 1.07 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.68 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Ehud Geller | CEO & Chairman |
| Ori Gon | CFO & CBO |
| Liora Sklair | VP R&D |
| Orly Amiran | VP Quality & Regulatory Affairs |
| Raz Simon | VP Product & Applications |
| Galit Reske | Chief Medical Officer |
| Nadya Lisovoder | Director of Clinical Operations |
Board
| Director | Role |
|---|---|
| Ehud Geller | CEO & Chairman |
| Efraim Cohen Arazi | Director |
| Jeff Dykan | Director |
| Keith Valentine | Director |
| Pini Ben-Elazar | Director |
| Susan Alpert | Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 23 slides | September 2026 |
| IPO Roadshow (May 2026) | IPO roadshow | 26 slides | May 29, 2026 |
| IPO Roadshow (October 2025) | IPO roadshow | 25 slides | Oct 6, 2025 |
| IPO Roadshow (July 2025) | IPO roadshow | 25 slides | Jul 7, 2025 |
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares (or pre-funded warrants) with ordinary warrants Announced: about US$6.5M · US$3.5 a share · Warrants at US$4.2 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: GelrinC pivotal trial and FDA PMA preparation, Gelrin platform, manufacturing scale-up, European market entry, working capital | Jun 18, 2026 |
| Public offering of ordinary shares Closed: US$10M raised · US$8 a share · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Development activities including completing its pivotal trial and PMA submission prep for GelrinC, plus debt repayment and deferred compensation | Dec 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$8.00 a share on Dec 3, 2025.
- Price
- US$8.00 a share
- Shares offered
- 1,250,000 ordinary shares
- Offering size
- US$10 million
- Underwriters' option
- Up to 187,500 more shares
- Listing
- RGNT on NYSE American
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Dec 5, 2025
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 21, 2024 |
| Filed publicly | Mar 11, 2025 |
| Amended 6 times | Newest Oct 24, 2025 |
| Shares registered with an exchange | Sep 9, 2025 |
| Final prospectus, with the price | Dec 4, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B3 · Prospectus | Dec 4, 2025 |
| CERT · Exchange's certificate of listing | Dec 3, 2025 |
| FWP · Free writing prospectus | Oct 24, 2025 |
| F-1/A · Registration statement, amended | Oct 24, 2025 |
| FWP · Free writing prospectus | Oct 6, 2025 |
| F-1/A · Registration statement, amended | Sep 30, 2025 |
| CORRESP · Letter to the SEC | Sep 17, 2025 |
| CORRESP · Letter to the SEC | Sep 17, 2025 |
| CORRESP · Letter to the SEC | Sep 15, 2025 |
| CORRESP · Letter to the SEC | Sep 15, 2025 |
All 34 filings
Open IPO · From the cover of the final prospectus (424B3) filed Dec 4, 2025
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Research and development | 331.0K | 1.64M | 806.0K | 971.0K |
| Selling, general and administrative | 8.29M | 712.0K | 1.13M | 436.0K |
| Operating income | -6.97M | 932.0K | -1.93M | -1.41M |
| Interest expense | 79.0K | 10.0K | 173.0K | 0 |
| Income before tax | 13.6M | -4.80M | 4.13M | -1.45M |
| Net income | -13.6M | 4.80M | -4.13M | -1.45M |
| Earnings per share, basic | -24.16 | 1.72 | -24.09 | -0.29 |
| Earnings per share, diluted | -24.16 | 1.72 | -24.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 7.38M | 229.0K | 345.0K | 1.24M |
| Current assets | 7.62M | 482.0K | 360.0K | 1.72M |
| Total assets | 7.62M | 482.0K | 360.0K | 1.72M |
| Accounts payable | 266.0K | 252.0K | 353.0K | 206.0K |
| Current liabilities | 2.87M | 6.49M | 3.14M | 2.61M |
| Long-term debt | 7.41M | 6.47M | ||
| Total liabilities | 2.87M | 6.49M | 46.3M | 43.8M |
| Shareholders' equity | 4.74M | -41.1M | -45.9M | -42.1M |
| Shares outstanding | 5.18M | 162.2K | 5.18M | 4.93M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -1.38M | -641.0K | -1.22M | -1.50M |
| Capital spending | 0 | 0 | 0 | 0 |
| Free cash flow | -1.38M | -641.0K | -1.22M | -1.50M |
| Cash from financing | 8.52M | 525.0K | 325.0K | 0 |
| Change in cash | 7.15M | -116.0K | -895.0K | -1.50M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 23, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Sep 17, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 11, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 15, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 14, 2026 | Other filings | SEC |
All 94 filings
Cap table
Built by 6ix from Regentis Biomaterials Ltd.’s releases · as of Jun 18, 2026
- Common shares
- 7,023,921
- Fully diluted
- 7,023,921
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 7,023,921 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 7,023,921 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Keith Valentine Other companies: Alphatec Holdings, Inc. (Director · Since at least Jul 29, 2024); Orthofix Medical Inc. (President & CEO, Director · Jan 5, 2023 – Feb 28, 2023 · Past); SI-BONE, Inc. (Director · Oct 16, 2018 – Jun 9, 2023 · Past); SeaSpine Holdings Corp (Chief Executive Officer, Director · Jun 11, 2015 – Jan 5, 2023 · Past); NuVasive Inc (COO · Jan 3, 2006 – Jan 27, 2015 · Past) | Director · Since at least Mar 18, 2026 |
| Arie Gordashnikov Other companies: Core AI Holdings, Inc. (Chief Financial Officer · Since at least Jul 1, 2026) | Chief Accounting Officer · Since at least Mar 18, 2026 |
| Efraim Cohen Arazi Other companies: PRF Technologies Ltd. (Interim CEO, Director · Since at least Mar 18, 2026) | Director · Since at least Mar 18, 2026 |
| Ehud Geller Other companies: PRF Technologies Ltd. (Executive Chairman & Interim CEO · Since at least Mar 18, 2026) | CEO & Chairman · Since at least Mar 18, 2026 |
| Jeff Dykan Other companies: Lifeward Ltd. (Director · Dec 31, 2015 – Sep 13, 2023 · Past) | Director · Since at least Mar 18, 2026 |
| Ori Gon Other companies: Lifeward Ltd. (Chief Financial Officer · Feb 22, 2018 – Jun 30, 2021 · Past) | CFO & CBO · Since at least Mar 18, 2026 |
| Susan Alpert Other companies: Medtronic plc. (SrVP Chief Regulatory · Jun 8, 2006 – Aug 3, 2009 · Past) | Director · Since at least Mar 18, 2026 |
| Galit Reske | Chief Medical Officer · Since at least Mar 18, 2026 |
| Liora Sklair | VP R&D · Since at least Nov 5, 2026 |
| Nadya Lisovoder | Director of Clinical Operations · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Orly Amiran | VP Quality & Regulatory Affairs · Since at least Nov 5, 2026 |
| Pini Ben-Elazar | Director · Since at least Mar 18, 2026 |
| Raz Simon | VP Product & Applications · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Regentis Biomaterials Ltd.